SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

ABSTRACT: Background:Glioblastoma (GBM) is one of the most aggressive human brain tumors, with a median survival of 15-18 months. There is a desperate need to find novel therapeutic targets. Various receptor protein kinases have been identified as potential targets; however, response rates in clinical studies have been somewhat disappointing. Targeting the spleen tyrosine kinase (SYK), which acts downstream of a range of oncogenic receptors, may therefore show more promising results. Methods:Kinase expression of brain tumor samples including GBM and low-grade tumors were compared with normal brain and normal human astrocytes by microarray analysis. Furthermore, SYK, LYN, SLP76, and PLCG2 protein expressions were analyzed by immunohistochemistry, western blot, and immunofluorescence of additional GBM

SUBMITTER: Moncayo G 

PROVIDER: S-EPMC5892144 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature